Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
XGN - Exagen Inc
-0.13(-5.14%)9:00:00 PM 12/2/2022
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
Stock Statistics
PE Ratio
PEG Ratio
P/S (ttm)6.2
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %4%
Held by Institutions %74%
1 Day Vol Adjusted Return-0.4
1 Month Vol Adjusted Return0.3
3 Month Vol Adjusted Return-5.2
6 Month Vol Adjusted Return-7.1
20 Days SMA Price ZScore-0.5
50 Days SMA Price ZScore-0.5
12 -26 Days PPO0.3
1 Month Average Short Volume Ratio35.4
1 Day Volume Change ZScore-0.4
1 Month Daily Vol13.4
Related Topics
leak data

Related Topics


Related Peers

Stock news

    Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

    Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    Exagen Inc. Reports Third Quarter 2022 Results

    Medicare Reimbursement ReturnsSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights: Total revenue of $14.7 million recognized in the third quarter of 2022. Our flagship AVISE® CTD test, including AVISE® Lupus, recognized revenue of $12.8 million in the third quarter of 2022.Delivered 35,569 AVISE CTD tests, including AVISE Lupu

    Exagen Inc. to Participate in Fourth Quarter Investor Conferences

    SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth quarter investor conferences. Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Thursday, November 17, 2022, at the Westin NY Grand Central Hotel Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference Panel Presentation - Diagnostics Tool Time: No

    Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022

    SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022. John Aballi, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT). Interested parties

    Exagen Announces Appointment of John Aballi as CEO

    SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. The Exagen Board has appointed Mr. Aballi as CEO, President, and a member of the Board. Mr. Aballi is an executive with a broad range of experience in growth-stage companies in the clinical diagnostic

    Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

    SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In this role, Dr. Concoff will lead the company’s rheumatoid arthritis medical initiatives, including the AVISE® RADR platform (Rheumatoid Arthritis Drug Response). Dr. Concoff will be a key principal in strategy, business development, portfolio management, pipeline prioritiza

    Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting

    SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2022, being held November 10-14, 2022, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Selected as a Featured Poster and ACR’s Ignite Talk is “Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurat

    The past three years for Exagen (NASDAQ:XGN) investors has not been profitable

    Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So...

    Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

    SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory University has led to a publication in Nature, found here. Exagen’s clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection. In addition, these retrospective analyses laid the groundwork for th